ClinicalTrials.gg
CompletedNCT05803369Updated Oct 22, 2026

DOD Regulating Together Intervention

An interventional study of Regulating Together (RT) and Achieving Independence and Mastery in School (AIMS) in Autism Spectrum Disorder and Emotion Regulation, sponsored by Children's Hospital Medical Center, Cincinnati. Completed at 1 site in United States. Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2022, registered Mar 2023).
Updated Oct 22, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
8 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Autism Spectrum Disorder by Children's Hospital Medical Center, Cincinnati — 6 open to participants now, 6 under way, none of them phase 3. Autism Spectrum Disorder · Children's Hospital Medical Center, Cincinnati.

Enrollment
6th of 19
125 · median 52
Started
2022
the only one that year
No phase
14 of 21
5 open now
Registered
13th of 21
by date

Among the 21 studies in Autism Spectrum Disorder by Children's Hospital Medical Center, Cincinnati, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 14 with no phase, and was the 13th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

6 of the 21 studies in Autism Spectrum Disorder by Children's Hospital Medical Center, Cincinnati are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 8 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Autism Spectrum Disorder by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

Our long-term goal is to validate Regulating Together (emotion regulation intervention) and improve psychosocial outcomes for youth with autism spectrum disorder and emotion dysregulation.

Read the detailed description

144 children ages 8-12 years old with autism spectrum disorder will be enrolled in the study and randomized to Regulating Together (RT) or Achieving Independence and Mastery in School (AIMS) groups. Participants will complete assessments at five time points: Screen (T1) Week 0 - where they will complete consent; Baseline (T2); Week 7: Post Active Treatment (includes semi-structured interviews) (T3); Week 16: Post Generalization (T4); Week 29: Final outcome visit (T5). Participants will receive 5 weeks of intervention, twice per week, following the T2 visit.

03

Conditions studied

  • Autism Spectrum Disorder
  • Emotion Regulation

Keywords

  • Regulating Together
04

Who can participate

Ages eligible
8 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of autism spectrum disorder (ASD)
  • A Full Scale IQ score of 65 or greater on the Weschler Abbreviated Scale Intelligence (WASI-II) or other previous Weschler IQ test
  • Concern of emotion dysregulation (ED) as measured by a score of 6 or greater on the Emotion Dysregulation Inventory-Reactivity (EDI-R).
  • Caregivers and child are fluent in speaking English
  • Child functional verbal communication, confirmed via appropriateness for an Autism Diagnostic Observation Schedule (ADOS-2) Module 3.
  • Family willing to keep prescribed medication and outside interventions stable
  • willing to participate in twice weekly 90-minute sessions of either Regulating Together (RT) or Achieving Independence and Mastery in School (AIMS).
  • The guardian must provide written on behalf of the participant and the participants ages 11-12 years old must provide written informed assent to participate.

Exclusion criteria

Exclusion Criteria:

  • Initiation of new psychosocial intervention within 30 days prior to randomization/first day of treatment.
  • any physical aggression toward other children outside the home in the past 2 weeks that resulted in serious injury
  • Presence of comorbid major neuropsychiatric illness warranting other treatment approaches.
  • Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Regulating Together (RT)

    Participants will receive Regulating Together -the emotion dysregulation intervention

    Behavioral: Regulating Together (RT)

  • Active comparator
    Achieving Independence and Mastery in School (AIMS)

    Participants will receive AIMS, the academic functioning/organizational skill intervention.

    Behavioral: Achieving Independence and Mastery in School (AIMS)

Interventions

  • BehavioralRegulating Together (RT)

    Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.

  • BehavioralAchieving Independence and Mastery in School (AIMS)

    AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.

06

What researchers measure

Primary outcomes

  1. Emotion Dysregulation Inventory- Reactivity

    13-item parent report measure that captures negative emotional responses and Dysphoria characterized by increased negative affect and lack of motivation. Higher scores mean higher emotional reactivity.

    Time frame: Through study completion, about 29 weeks

Secondary outcomes

  1. Children's Organizational Skills Scale (COSS)

    Used to measure outcomes from AIMS intervention. It is a rating scale completed by parents and teachers which yields three factors measuring Organized Actions, Task Planning, and Memory and Materials Management. Higher scores mean higher organizational skills.

    Time frame: Through study completion, about 29 weeks

  2. Daily Phone Diary

    Phone interview administered by staff that documents Frequency and Intensity of Behavioral and Emotional Outbursts over a 2 day period.

    Time frame: Through study completion, about 29 weeks

  3. Inpatient Hospitalization Rates

    chart review and caregiver report for any psychiatric hospitalizations

    Time frame: during the 6 months prior to enrollment in the study and during the 6 months after completion of the individualized consult

07

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
08

References and documents

Publications

  • Kang S, Burkett K, Sarawgi S, Ruberg J, Paustian J, Reisinger DL, Schmitt LM, Shaffer RC. Regulating Together: Caregivers' experiences in a shared journey through an emotion dysregulation intervention for autistic youth. Res Dev Disabil. 2026 Jul;174:105317. doi: 10.1016/j.ridd.2026.105317. Epub 2026 May 31. PubMed 42217453 ↗
  • McKinney WS, Tadevich LJ, Schmitt LM, Horn PS, Ruberg JR, White SW, Reisinger DL, Burkett KW, Sarawgi S, Kang S, Shaffer RC. Study protocol for a randomized controlled trial of Regulating Together (RT), a group therapy for emotion dysregulation in school-age autistic youth and their caregivers. BMC Psychol. 2025 Apr 24;13(1):436. doi: 10.1186/s40359-025-02737-6. PubMed 40275407 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jun 2026, 46 months.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 46 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion May 2026 → Jun 2026 and completion Jul 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Apr 7, 2023
StartActual
Aug 1, 2022
Primary completionActual
Jun 2, 2026was May 2026
CompletionActual
Jun 2, 2026was Jul 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 22, 2026
Primary completion
May 31, 2026→Jun 2, 2026 (actual)
Oct 22, 2026
Study completion
Jul 1, 2026→Jun 2, 2026 (actual)
Oct 22, 2026
Enrollment
144 (estimated)→125 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Completed
    Primary completion May 31, 2026→Jun 2, 2026 (now actual)
    Study completion Jul 1, 2026→Jun 2, 2026 (now actual)
    Enrollment 144 (estimated)→125 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05803369
Collaborators
United States Department of Defense, University of Alabama at Birmingham
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Aug 1, 2022
Primary completion
Jun 2, 2026
Completion
Jun 2, 2026
Last update
Oct 22, 2026

Study contacts

Rebecca Shaffer
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion